Trials / Completed
CompletedNCT01010789
Armodafinil in Binge Eating Disorder (BED)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Lindner Center of HOPE · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to study the effectiveness, tolerability and safety of armodafinil in outpatients with binge eating disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Armodafinil | flexible dose 150-250mg/day |
| DRUG | Armodafinil | 150-250mg/day; flexible dose |
| DRUG | Matching placebo | Placebo comparator |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2014-11-01
- Completion
- 2015-05-01
- First posted
- 2009-11-10
- Last updated
- 2015-05-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01010789. Inclusion in this directory is not an endorsement.